​
​

Fortress Biotech (FBIO) Revenue & Revenue Breakdown

OverviewOwnershipFinancialsChart

Fortress Biotech Revenue Highlights

Latest Revenue (Y)

$59.66M

Latest Revenue (Q)

$14.63M

Main Segment (Y)

Qbrexza

Fortress Biotech Revenue by Period

Fortress Biotech Revenue by Year

DateRevenueChange
2023-12-31--21.23%
2022-12-31-10.11%
2021-12-31-50.86%
2020-12-31-24.49%
2019-12-31-36.26%
2018-12-31--85.67%
2017-12-31-1038.25%
2016-12-31-1809.62%
2015-12-31-100.00%
2014-12-31-100.00%
2013-12-31-100.00%
2012-12-31-100.00%
2011-12-31-100.00%
2010-12-31--

Fortress Biotech generated $59.66M in revenue during NA 2023, up -21.23% compared to the previous quarter, and up 221.94% compared to the same period a year ago.

Fortress Biotech Revenue by Quarter

DateRevenueChange
2024-09-30--1.79%
2024-06-30-14.32%
2024-03-31--34.67%
2023-12-31--42.60%
2023-09-30-99.88%
2023-06-30-39.88%
2023-03-31--24.23%
2022-12-31--0.75%
2022-09-30--12.49%
2022-06-30--21.06%
2022-03-31-30.91%
2021-12-31--13.32%
2021-09-30-18.17%
2021-06-30-53.99%
2021-03-31--15.72%
2020-12-31-45.11%
2020-09-30-0.19%
2020-06-30--26.79%
2020-03-31-16.06%
2019-12-31-13.90%
2019-09-30-5.64%
2019-06-30-42.81%
2019-03-31--104.15%
2018-12-31--345.03%
2018-09-30--0.22%
2018-06-30-15.17%
2018-03-31-22.30%
2017-12-31--3.34%
2017-09-30--7.52%
2017-06-30-13.46%
2017-03-31-254.20%
2016-12-31-1193.85%
2016-09-30--56.28%
2016-06-30-237.88%
2016-03-31-95.27%
2015-12-31-1252.00%
2015-09-30-100.00%
2015-06-30--100.00%
2015-03-31-100.00%
2014-12-31-100.00%
2014-09-30-100.00%
2014-06-30-100.00%
2014-03-31-100.00%
2013-12-31-100.00%
2013-09-30-100.00%
2013-06-30-100.00%
2013-03-31-100.00%
2012-12-31-100.00%
2012-09-30-100.00%
2012-06-30-100.00%
2012-03-31-100.00%
2011-12-31-100.00%
2011-09-30-100.00%
2011-06-30-100.00%
2011-03-31-100.00%
2010-12-31-100.00%
2010-09-30--

Fortress Biotech generated $14.63M in revenue during Q3 2024, up -1.79% compared to the previous quarter, and up 84.14% compared to the same period a year ago.

Fortress Biotech Revenue Breakdown

Fortress Biotech Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21Dec 20Dec 19
Zilxi-----
Accutane-----
Amzeeq-----
Exelderm-----
Qbrexza-----
Targadox-----
Ximino-----
Other Branded Revenue-----
Pharmaceutical And Biotechnology Product Development-----
Dermatology Products Sales-----
Return Reserve-----
License And Service-----
Royalty-----

Fortress Biotech's latest annual revenue breakdown by segment (product or service), as of Dec 23: Qbrexza (42.61%), Accutane (33.82%), Amzeeq (10.40%), Targadox (5.37%), Exelderm (4.02%), Zilxi (3.29%), and Ximino (0.48%).

Quarterly Revenue by Product

Product/ServiceJun 24Mar 24Dec 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19
Qbrexza--------------------
Accutane--------------------
Zilxi--------------------
Amzeeq--------------------
Ximino--------------------
Exelderm--------------------
Targadox--------------------
Other Branded Revenue--------------------
Dermatology Products Sales--------------------
Pharmaceutical and Biotechnology Product Development--------------------
Pharmaceutical And Biotechnology Product Development--------------------
Consolidated--------------------

Fortress Biotech's latest quarterly revenue breakdown by segment (product or service), as of Jun 24: Qbrexza (48.38%), Accutane (40.48%), Amzeeq (8.53%), and Zilxi (2.61%).

Fortress Biotech Revenue Breakdown by Country

Quarterly Revenue by Country

CountryMar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Dec 18Sep 18Jun 18
Accutane--------------------
Exelderm--------------------
Qbrexza--------------------
Targadox--------------------
Ximino--------------------
Zilxi--------------------
Amzeeq--------------------
Other Branded Revenue--------------------
Dermatology Products Sales--------------------
Pharmaceutical and Biotechnology Product Development--------------------
Pharmaceutical And Biotechnology Product Development--------------------
Consolidated--------------------
License and Service--------------------
Other branded revenue--------------------

Fortress Biotech's latest quarterly revenue breakdown by geography, as of Mar 23: Accutane (38.21%), Qbrexza (33.65%), Amzeeq (9.81%), Targadox (6.52%), Ximino (5.03%), Exelderm (4.20%), and Zilxi (2.58%).

Fortress Biotech Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ACADACADIA Pharmaceuticals--
FBIOFortress Biotech--
PIRSPieris Pharmaceuticals--
LUMOLumos Pharma--
CKPTCheckpoint Therapeutics--
EYENEyenovia--
APTOAptose Biosciences--
MBIOMustang Bio--
CABACabaletta Bio--
RVPHReviva Pharmaceuticals--
ALRNAileron Therapeutics--
ATHAAthira Pharma--
CGTXCognition Therapeutics--
ACHLAchilles Therapeutics--
ATXIAvenue Therapeutics--
KODKodiak Sciences--
RNAZTransCode Therapeutics--

FBIO Revenue FAQ

What is Fortress Biotech’s yearly revenue?

Fortress Biotech's yearly revenue for 2023 was $59.66M, representing a decrease of -21.23% compared to 2022. The company's yearly revenue for 2022 was $75.74M, representing an increase of 10.11% compared to 2021. FBIO's yearly revenue for 2021 was $68.79M, representing an increase of 50.86% compared to 2020.

What is Fortress Biotech’s quarterly revenue?

Fortress Biotech's quarterly revenue for Q3 2024 was $14.63M, a -1.79% decrease from the previous quarter (Q2 2024), and a -57.90% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $14.9M, a 14.32% increase from the previous quarter (Q1 2024), and a -14.32% decrease year-over-year (Q2 2023). FBIO's quarterly revenue for Q1 2024 was $13.03M, a -34.67% decrease from the previous quarter (Q4 2023), and a 4.84% increase year-over-year (Q1 2023).

What is Fortress Biotech’s revenue growth rate?

Fortress Biotech's revenue growth rate for the last 3 years (2021-2023) was -13.27%, and for the last 5 years (2019-2023) was 62.88%.

What are Fortress Biotech’s revenue streams?

Fortress Biotech's revenue streams in c 23 are Zilxi, Accutane, Amzeeq, Exelderm, Qbrexza, Targadox, and Ximino. Zilxi generated $1.96M in revenue, accounting 3.29% of the company's total revenue, down -13.68% year-over-year. Accutane generated $20.17M in revenue, accounting 33.82% of the company's total revenue, up 9.77% year-over-year. Amzeeq generated $6.2M in revenue, accounting 10.40% of the company's total revenue, down -14.37% year-over-year. Exelderm generated $2.4M in revenue, accounting 4.02% of the company's total revenue, down -30.84% year-over-year. Qbrexza generated $25.41M in revenue, accounting 42.61% of the company's total revenue, down -4.88% year-over-year. Targadox generated $3.2M in revenue, accounting 5.37% of the company's total revenue, down -59.81% year-over-year. Ximino generated $287K in revenue, accounting 0.48% of the company's total revenue, down -94.21% year-over-year.

What is Fortress Biotech’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Fortress Biotech was Qbrexza. This segment made a revenue of $25.41M, representing 42.61% of the company's total revenue.